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Disclosure
• IRB Status: Approved; Study2019000511
• Study design
• Retrospective cohort study
• Study timeline
• Data collection: August 2019 – March 2020
• Inclusion criteria
• Started a new specialty medication for an inflammatory 
condition
• Received ≥1 pharmacist Specialty Medication Management 
Services (SMMS) Inflammatory Assessment follow-up attempt
• Exclusion criteria 
• Patients who have opted out of SMMS program
• Patients age <18 years
• Standardized pharmacist follow-up occurs at month 1 and 4 after 
the patient receives their refill
• Deviations are defined as consultations occurring at month 2 or 3, 
as these are outside of the standard follow-up intervals outlined in 
the frequency guide. 
• Interventions are defined as any pharmacist (RPh) action taken to 
help improve clinical outcomes for the patient such as  adherence 
concerns, identifying drug interactions, side effect management, 
product/stability (P/S) questions, etc. 
Primary Objective
• There were a total of 36 deviations: 26 at month 2, 10 at month 3
• By primary condition (Fig. 1), most deviations were seen with Ps 
(n=8, 22.2%), followed by PsA, AS, and RA (each: n=7, 19.4%) 
• By medication (Fig. 2), most deviations were associated with 
adalimumab (n=12, 33.3%), and secukinumab (n=9, 25%), while all 
other medications shared similar frequency of deviations ranging 
from n=1-3, 2.8-8.3%.   
• Results were most likely influenced by the conditions/medications 
having the largest subpopulations of their categories.
• When evaluating by proportion of deviations reported per number 
of patients associated with primary condition or medication (Fig. 1 
and Fig. 2), the most common deviations were as follows: 
• Primary condition – AS (n=7, 70%), RA (n=7, 28%), SLE (n=1, 
25%) and MD (n=2, 25%)
• By medication – certolizumab pegol (n=2, 200%), 
guselkumab (n=2, 40%), secukinumab (n=9, 34.6%)
Secondary Objectives 
• Reasons for deviations included (Fig. 4): unable to reach patient 
during standardized follow-up frequency (41.7%), RPh clinical 
decision that sooner follow up was necessary (27.8%), patient 
initiated consult (25%), and RPh failed to attempt follow-up 
consultation at month 1 and/or 2 (5.6%)
• Thirty-six total deviations between months 2 and 3 resulted in 27 
interventions (Fig. 3).
• Most common interventions were due to medication 
reconciliation and side effect management 
• Pharmacist interventions (Fig. 6 & 7) were required most often for:
• PsA (n=26, 21.5%), Ps (n=21, 17.4%), and AD (n=16, 13.2%) 
• Adalimumab (n=39, 32.2%), secukinumab (n=19, 15.7%), 
and dupilumab (n=16, 13.2%) 
• Patients taking adalimumab reported missed or late doses most 
frequently (33.3% of the 24 reported). 
• QoL metrics (Table 2) were not consistently reported, however, 
there is notable improvement from baseline to month 4. At month 
0, average patient-reported QoL was 5.6 across all conditions, while 
after 4 months of treatment, QoL scores improved to 3.6. 
• Tofacitinib and AS required the most pharmacist consultation time.
• tofacitinib averaged 13.2 minutes per consultation
• AS averaged 15.2 minutes per consultation
• Monthly average consultation time was consistent across all 
months, ranging from 10.3-10.7 minutes per consultation 
Medications and/or conditions that did not have any results to report were omitted from the tables and 
charts in the “Results” section.
Month 0 was excluded from most of the data as this was the initiation assessment all patients were 
required to completed and not considered a follow-up assessment. 
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• Monitoring for non-adherence, side effects, laboratory parameters, 
and health status changes is essential for patients diagnosed with 
inflammatory conditions, especially those initiating targeted 
therapy.1,2
• Pharmacist involvement with medication therapy management 
positively impacts patient health outcomes, but the benefit of a 
standardized clinical follow-up assessment frequency is lacking in 
specialty pharmacy literature.3
• One study evaluated the interventions made by pharmacists prior to 
a standardized frequency follow-up guide to determine optimal 
consultation intervals.4
• This study implemented the standardized follow-up frequency guide 
determined from the previous study. 
• The standardized pharmacist follow-up frequency guide provides a 
clinically meaningful strategy to monitor and follow-up with 
patients prescribed high-cost, high-risk inflammatory disease-
modifying therapies. 
• By establishing that the majority of clinically significant 
interventions occurred during the standardized frequency intervals, 
this guide accomplished maintaining patient safety, in addition to 
aiding patients with their clinical goals and overall quality of life. 
• In addition, this data supports continuing a standard follow-up 
frequency at month 1 and 4 by demonstrating that no critical 
interventions were missed and most deviations occurred due to 
pharmacists inability to reach patients during the pre-defined 
intervals.
• One limitation of this study was the inconsistent reporting of QoL 
metrics.
• It is reasonable for specialty pharmacists to utilize a standardized 
follow-up frequency guide that provides flexibility for modifications 
based on clinical judgment to manage patients diagnosed with an 
inflammatory condition.
Purpose
• Evaluate the clinical value and utility of a standardized pharmacist 
follow-up frequency in patients prescribed inflammatory disease-
modifying therapies.
• Determine if any frequency changes are necessary to optimize the 
follow-up intervals for specific inflammatory conditions or specialty 
medications. 
Methodology
Results
Health & Services
References
• Rochelle Castrillo: Nothing to disclose
• Adam Saulles: Nothing to disclose
• Primary objective
• Determine quantity of pharmacist deviations from the follow-
up frequency guide by inflammatory condition and medication 
regimen
• Secondary objectives
• Categorize and assess the reasons for pharmacist deviation 
from the guide 
• Assess quantity and types of pharmacist interventions made 
during deviations from the guide by medication and condition
• Evaluate patient reported medication adherence and quality-of-
life (QoL) metrics
• Calculate pharmacist time spent per assessment
• Tara Berkson: Nothing to disclose
• Linda Huynh: Nothing to disclose
Secondary Objectives
Primary Objective
Demographics Study Group N=154
Age, years, mean 46 (range 20-73)
Sex, female, No. (%) 102 (66.2)
Primary Condition, No. (%) Study Group N=154
Psoriasis (Ps) 39 (25.3)
Psoriatic Arthritis (PsA) 30 (19.5)
Rheumatoid Arthritis (RA) 25 (16.2)
Atopic Dermatitis (AD) 17 (11.0)
Ankylosing Spondylitis (AS) 10 (6.5)
Multiple Diagnoses (MD) 8 (5.2)
Ulcerative Colitis (UC) 7 (4.5)
Other 6 (3.9)
Crohn’s Disease (CD) 4 (2.6)
Systemic Lupus Erythematosus (SLE) 4 (2.6)
Hidradenitis Suppurativa (HS) 3 (1.9)
Uveitis (Uv) 1 (0.6)
Primary Medication(s), No. (%) Study Group N=154
adalimumab 45 (29.2)
secukinumab 26 (16.9)
dupilumab 17 (11.0)
tofacitinib 12 (7.8)
etanercept 11 (7.1)
risankizumab-rzaa 10 (6.5)
apremilast 9 (5.8)
ustekinumab 5 (3.2)
tocilizumab 4 (2.6)
belimumab 4 (2.6)
ixekizumab 4 (2.6)
guselkumab 4 (2.6)
certolizumab pegol 1 (0.6)
abatacept 1 (0.6)
golimumab 1 (0.6)
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Table 2 – Monthly Quality of Life Scores per Condition 
Condition Month 0 (n) Month 1 (n) Month 4 (n)
AS 6.4 (8) 5 (1) 4.5 (2)
AD 5.3 (11) 2.5 (6) 2 (4)
CD 7.5 (4) 6 (1) 4 (2)
HS 7.5 (2) N/A (0) N/A (0)
MD 6.9 (7) 2 (1) N/A (0)
Other 7 (2) 7 (2) 6 (1)
Ps 5.4 (25) 4.7 (7) 1.2 (5)
PsA 5.9 (24) 2.5 (4) 4.3 (7)
RA 4.9 (23) 3.8 (6) 5.5 (4)
SLE 5.5 (2) N/A (0) N/A (0)
UC 4.8 (6) 5 (1) 5 (1)
Uv 5 (1) N/A (0) N/A (0)
Overall Average 5.6 (115) 3.9 (29) 3.6 (26)
Scale 0-10; 0 = excellent QoL, 10 = poor QoL
Figure 5
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